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Abstract
Cerebral venous thrombosis (CVT) is an uncommon disorder in the general population. 
At least 1 risk factor can be identified in 85% of patients with CVT. Because of the high 
frequency of thrombophilia among patients with CVT, screening for hypercoagulable 
conditions should be performed. Two pathophysiological mechanisms contribute to their 
highly variable clinical presentation. Four major syndromes have been described: isolated 
intracranial hypertension, focal neurological abnormalities, seizures, and encephalopathy. 
Cavernous sinus thrombosis represents the single CVT which produces a characteristic clin-
ical syndrome. Head Computed Tomography is the most frequently performed imaging 
study, but Magnetic Resonance Imaging of the head combined with Magnetic Resonance 
venography are the most sensitive studies. Acute phase therapy for CVT focuses on anti-
coagulation, management of seizures, increased intracranial pressure, and prevention of 
cerebral herniation. The majority of patients have a complete or partial recovery, how-
ever they have an increased incidence of venous thromboembolism. Clinical and imaging 
follow-ups 3–6 months after diagnosis are recommended to assess for recanalization.
Keywords: cerebral venous thrombosis, thrombophilia, isolated intracranial 
hypertension, magnetic resonance imaging of the head, magnetic resonance 
venography, anticoagulation
1. Introduction
Rare (0.5–1% of all strokes), but alarming disease, cerebral venous thrombosis (CVT) has a higher 
frequency among young adults (<40 years of age), patients with thrombophilia, and women 
who are pregnant or using oral contraceptives [1–4]. The most frequent symptoms are headache, 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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papilledema, seizures, motor, sensory or language deficits, altered mental status and decreased 
consciousness. CVT can be caused by multiple predisposing conditions and precipitants. At 
least one risk factor can be identified in more than 85% cases, multiple risk factors, in about ½ of 
patients, while in less than 15% no underlying cause can be found [1, 2, 5]. Contemporary brain 
imaging techniques [angiography, magnetic resonance imaging (MRI) and magnetic resonance 
angiography (MRA)] allow the diagnosis of benign forms of CVT with minimal, nonspecific 
symptoms and spontaneous recovery [1, 3]. The CVT treatment is based on a combination of 
etiologic and symptomatic medications. Currently, the main treatment of choice for CVT is hep-
arin (intravenous heparin or subcutaneous low-molecular-weight heparin) in therapeutic dos-
ages [1, 5]. The CVT prognosis depends on the early detection, but it should be mentioned that 
mortality trends have diminished over the last decades [6]. Because of its frequently misleading 
presentation, its wide spectrum of causes, its unpredictable course, and its occasional treatment 
problems, CVT remains a challenge for the clinician [1, 6]. We also want to emphasize that, 
due to its features, CVT should remain a disease of interest not only for neurologists, but also 
for other specialists – neurosurgeons, ear, nose and throat (ENT) specialists, ophthalmologists, 
hematologists, obstetricians, internists, and oncologists [5].
2. Dural sinuses and encephalic veins anatomy
2.1. Encephalic veins
The veins within the cranium contain approximately 70% of the cerebral blood volume (Figure 1) 
[7]. Blood of the brain is drained by the cerebral venous system which consists of the cerebral veins 
and dural venous sinuses. The cerebral veins don’t follow the same path as the arteries. Emerging 
as fine branches from the substances of the brain, the cerebral venous blood vessels form a pial 
plexus from which arise the larger venous channels (cerebral veins) which empty into the sinuses 
of the dura mater. Cerebral veins have thin walls and no valves; they are linked by multiple anas-
tomoses, which allows the development of a collateral circulation and the reversal of blood flow 
toward the head and brain if there is an occlusion [1, 5, 8, 9].
Cerebral veins comprise three groups: (a) the superficial venous system, (b) deep venous system, 
and (c) posterior fossa veins: [5].
a. Due to its high proportion of number, course, and anastomoses, the superficial cerebral (cor-
tical) venous system is difficult to diagnose in cases of occlusion. The superficial veins are 
divided into superior, middle (sylvian), and inferior cerebral groups. They drain the ma-
jor part of the cerebral cortex. The superficial cerebral veins are linked by Trolard’s great 
anastomotic vein, which connects the superior sagittal sinus (SSS) to the middle cerebral 
veins, which are themselves connected to lateral sinus (LS) by Labbé’s vein. The frontal, 
parietal and occipital superior cerebral veins drain into the SSS. The middle cerebral veins 
consist of a superficial and a deep vein. The superficial middle vein empty into the cavern-
ous sinus, while the deep one, drain into the basal veins of Rosenthal [1, 5–7, 9].
b. Deep white matter, the corpus callosum, the basal ganglia, and the upper brainstem are 
drained by internal cerebral and basal (Rosenthal) veins which join to form the great vein of 
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Galen and empty, together with the inferior sagittal sinus (ISS), into the straight sinus (SS). 
In contrast to the superficial veins, the deep system is consistent and is always visualized 
at angiography, thus any thrombosis in this system is easily recognized [1, 3, 5, 6].
The two cerebral venous systems are connected through many anastomoses [6].
c. Veins of the posterior fossa may be divided into three groups: superior veins (draining into 
the galenic system), anterior veins (draining into the petrosal sinuses), and posterior veins 
(draining into the troncular and neighboring SS and LS). They are variable in course, and 
number making the angiographic diagnosis of their occlusion, extremely difficult [1, 5].
2.2. Dural sinuses
The dural sinuses represent a system of intercommunicating trabeculated endothelium-lined 
channels located between the meningeal and periostal layers of the dura (Figure 1). The walls 
of the sinuses are formed by the inner and outer fibrous layers of the dura mater. Inside of 
dural sinuses are found the Pacchioni’s or arachnoid granulations, which play an essential 
role in the cerebrospinal fluid (CSF) resorption, especially in SSS and SL [6, 9].
The major dural sinuses are: SSS, ISS, LS, cavernous sinus and SS; they empty into the two 
internal jugular veins (IJV) to drain into the superior vena cava. Dural sinuses are divided into 
posterior-superior (P-S) and antero-inferior groups (A-I). P-S comprises the SSS, ISS, LS, SS, 
and occipital sinus. The A-I group includes the superior and inferior petrosal sinuses and the 
cavernous sinus. The confluence of the sinuses (torcular herophili) is formed by the junction 
of SSS, straight, occipital and transverse sinuses [1, 5–7].
Figure 1. Dural sinuses and encephalic veins anatomy [70].
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The superior sagittal sinus (SSS) is located in the attached margin of falx cerebri, receives super-
ficial cerebral veins and drains the major part of the cerebral hemispheres. It also receives 
the diploe, dura mater, the scalp, and the pericranial veins which explains some cases of SSS 
thrombosis after cutaneous infections or head trauma. The SSS along with LS sinuses play 
an important role in CSF circulation, considering that CSF pressure depends directly on the 
intracranial venous pressure [1, 6, 7, 9].
Each lateral sinus (LS) consists of two sections: the transverse portion and the sigmoid portion 
which drain blood from cerebellum, brainstem, and posterior portions of the cerebral hemi-
spheres. They also receive some of the diploic veins and some small veins from the middle 
ear thus becoming vulnerable to infections thrombosis in patients with mastoiditis or otitis 
media. Asymmetry of the LS is frequent (50–80% of the cases) [1, 3, 6]. The right LS which is 
often a direct continuation of the SSS, is usually larger than the left so an isolated lack of fill-
ing of the left transverse sinus is thus suggestive more of hypoplasia than of thrombosis [1, 7].
Cavernous sinuses are complex, multiseptated extradural venous spaces located on each side 
of the sella turcica. They drain the blood from the orbits and from the anterior part of the base 
of the brain receiving superficial cortical veins, the ophthalmic (superior and inferior) and 
facial veins. Each cavernous sinus has important anatomical relations with other structures. 
Thus, the oculomotor and trochlear-cranial nerves, along with the ophthalmic and maxillary 
branches of the trigeminal nerves, traverse along the lateral wall of the cavernous sinuses, 
whereas the abducens nerve and the cavernous portion of the internal carotid artery (ICA) lie 
within the sinus itself. Infection is still the leading cause of cavernous sinuses thrombosis as a 
consequence to infections of the face or sphenoid sinusitis. The cavernous sinuses communi-
cate with each other via intercavernous sinuses and basilar venous plexus, and drain into the petro-
sal sinuses (superior and inferior) which empty into the sigmoid sinuses and the IJVs [1, 3, 6, 7].
The inferior sagittal sinus (ISS) receives blood from the corpus callosum and the cerebellum 
(through the deep cerebral veins) and it becomes continuous with SS [9].
The straight sinus (SS) is formed by the junction of ISS with the vein of Galen. It has a triangular 
lumen and is situated at the junction of the tentorium cerebelli with the falx cerebri. SS runs 
postero-inferiorly and ultimately joins torcular Herophili at the internal occipital protuber-
ance [9].
The occipital sinus is the smallest dural venous sinus, receiving tributaries from the margins of 
the foramen magnum. It runs along the inner surface of the occipital bone and may anastomo-
sis with the sigmoid sinuses and posterior internal vertebral plexus that drain into the torcular 
Herophili [10].
The internal jugular veins (IJV) are the continuation of the sigmoid sinus. They drain blood 
from the brain and the superficial parts of the face and neck. In contrast to the cerebral veins, 
they have valves in order to prevent blood going upwards in cases of increased intra-thoracic 
pressure [9].
The major cerebral venous outflow pathways are represented in adults by the IJV, for supine 
position, and the vertebral venous system for the upright position [11].
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3. Epidemiology
The prevalence of CVT is higher than previously reported probably because this rare type 
of stroke is now more frequently diagnosed due to an increased awareness and improved 
imaging techniques [12, 13]. CVT represent 0.5–1% of all strokes and may affect all age groups 
– from neonate to the very old [14]. CVT is more common in children than in adults, and 
among children, is more frequently diagnosed in neonates than in older children. The peak 
incidence in adults is in their third decade: the median age in the International Study on 
Cerebral Vein and Dural Sinus Thrombosis (ISCVT) cohort was 37 years, with only 8% of 
the patients older than 65 [5, 15–16]. CVT has a prominent differential sex prevalence, with 
a female-to-male ratio of approximately 3:1, with an even more marked difference in the age 
range of 31–50 years. The female predominance of CVT has been attributed to hormonal fac-
tors considering that the incidence is sex-independent in children and in the elderly [5, 16–18].
4. Risk factors
Several disorders can cause or predispose patients to CVT and often, this condition proves to 
be multifactorial, meaning that the identification of a risk factor or a cause should not deter 
from a search for other causes, in particular inherited or acquired thrombophilia [1, 3, 16, 19]. 
Supporting this affirmation, the ISCVT results showed that at least one risk factor can be identi-
fied in more than 85% of patients with CVT and multiple risk factors, in about half of them. The 
most frequent risk factors are prothrombotic conditions, oral contraceptive (OC) use, puerpe-
rium or pregnancy states, infection and malignancy. Among the CVT risk factors, thrombophilic 
disorders are the most frequent; only for the cavernous sinus, the main cause of thrombosis 
remains the skin infections of the face [5].
In the pre-antibiotic era, localized or systemic infections were the most common cause of dural sinus 
occlusions. Septic CVT is usually caused by pyogenic infections of the mastoid air cells, the 
paranasal sinuses, face, ears, scalp, or throat. It may also result as a complication of menin-
gitis, secondary to brain or epidural abscesses or after an open traumatic injury. However, 
since the introduction of antibiotics, septic thrombosis, has become a relatively rare, although 
severe condition [20].
In the 624 patients included in ISCVT, 34% had a form of thrombophilia and an inherited 
thrombophilic defect was detected in 22% of them. It is important to mention that usually an 
additional precipitating factor is present in patients with thrombophilia who develop CVT 
[4, 5, 16, 19].
Inherited thrombophilias are the main genetic disorders associated with CVT. Three highly prev-
alent mutations have been linked to thrombosis: factor V Leiden, factor II-the prothrombin vari-
ant (PT 20210A), and the homozygosity for MTHFR C677T. Among them, the factor V Leiden and 
the prothrombin gene mutation are the most frequent [3, 21–23]. The Q506 mutation in the gene 
coding for factor V (factor V Leiden) causes inherited resistance to activated protein C. Factor 
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V Leiden is the most prevalent inherited coagulation disorder and an important cause of CVT, 
being associated with a 9-fold higher risk, especially if females with this mutation take OC or 
become pregnant [12, 14, 20]. The prothrombin G20210A mutation (PT20210A) is considered the 
most important genetic thrombophilic risk factor associated with CVT. This mutation is present 
in about 2% of Caucasians causing an elevation of the plasmatic factor II level [14, 22]. According 
to Martinelli, PT20210A determines a 10-fold increase in the cerebral thrombosis risk, especially 
in OC users [12, 24]. Other genetic coagulation disorders reported to be involved in CVT include: 
plasminogen deficiency, decreased release of plasminogen activator, sickle cell disease (homozy-
gous sickle cell anemia), and elevated levels of factor VIII [20, 22].
Acquired thrombophilias. Antiphospholipid antibodies are directed against phospholipid-
binding plasma proteins and include anticardiolipin antibody and antibodies directed against 
β 2-glycoprotein. They were described in patients with lupus erythematosis, other connec-
tive tissue diseases and as isolated abnormalities, being strongly associated with arterial and 
venous thrombosis [21].
Antithrombin III and proteins C and S are natural inhibitors of coagulation. They can be defi-
cient on a hereditary basis or be reduced by disease. Congenital deficiency of antithrombin III 
may be quantitative or qualitative and is usually an autosomal-dominant condition. Inherited 
deficiencies of proteins C and S (both vitamin K dependent anticoagulants) can also contrib-
ute or cause hypercoagulability. Acquired deficiencies of antithrombin III may be associated 
with liver diseases or renal loss (nephrotic syndrome) [20].
Hyperhomocysteinemia (HHcy) is a disorder that is defined by an elevated plasma homo-
cysteine (Hy) concentrations. HHcy may have a toxic effect on the vascular endothelium 
affecting the clotting cascade. Increased plasma Hcy levels can be caused from several 
different genetic mutations in enzymes involved in Hcy metabolism (hereditary forms). 
Within these, the mutation of the MTHFR C677 → T gene is the most prevalent. There 
were also described acquired forms of HHcy which are determinated by low levels of folic 
acid, vitamin B6 or vitamin B12. HHcy is known to be associated with an increased risk 
for deep venous thrombosis (DVT) and arterial occlusive disease [12, 14, 19]. According 
to different studies, HHcy could be considered an independent and strong risk factor for 
CVT [19, 25, 26].
The gender-specific risk factors – pregnancy, postpartum state, oral contraceptive (OC) use and the 
hormone replacement therapy – are the most frequent risk factors in women with CVT, they 
being responsible for the marked feminine preference of this condition [4, 6, 18].
Pregnancy and puerperium In high-income countries, 5–20% of all CVT are related to preg-
nancy or puerperium, according to ISCVT, the peripartum etiologies being responsible for 
15% of CVT cases [16, 27–29] However, the incidence is much higher in low-income coun-
tries where puerperium is the most common risk factor for CVT accounting for 31% of cases 
[27, 30, 31]. Explanations for the frequency of intracranial venous thrombosis in pregnancy 
and the puerperium include poverty, absence of antenatal care, home delivery, vegetarian 
diet, depletion of vitamin and protein stores and dehydration associated with primipara and 
anemia [32]. Most pregnancy-related CVT occur in the third trimester or, more frequently, 
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in the first 3 week post-partum. In these cases, CVT could be accompanied by venous throm-
boses outside the nervous system (pelvic or lower extremity phlebothrombosis and pulmo-
nary embolism), probably, as a consequence of the hypercoagulable state and the venous 
stasis that occurs during pregnancy [3, 17, 20]. The prothrombotic changes induced by preg-
nancy include increasing of fibrinogen and several coagulation factors and decreasing of 
antithrombin III and plasminogen. These alterations in the coagulation system persist at 
least during early puerperium when the hypercoagulability worsens as a result of volume 
depletion, trauma and additional risk factors as infection, unhygienic environments, certain 
rituals, higher birth rates, instrumental delivery or cesarean section [3, 14, 28, 33, 34]. On the 
other hand, pelvic phlebothrombosis may determine CVT via the venous plexuses of the vertebral 
canal, and the basilar venous plexus.
Estrogens, whether administrated for contraception or therapeutic purposes (replacement 
therapy, suppression of lactation), are associated with a significant risk for venous and arterial 
thrombosis. Particularly, the administration of OC (especially the third-generation agents) is 
considered to be an independent risk factor for CVT, the great majority of younger no preg-
nant women with this condition being OC users [3–5, 14]. It is also important to mention that 
the risk of thrombosis, whether intra- or extracerebral in women taking OC is almost 6 times 
higher than that of non-users if this contraception method is combined with an underlying 
hereditary prothrombotic abnormality like those listed above [5, 14, 17, 35]. In most of the 
cases, the use of OC is found together with other conditions such as systemic lupus erythema-
tosus, Behçet’s disease or inherited thrombophilia. However, in about 10% of the CVT cases, 
the prothrombotic effect of OC remains the only identifiable etiologic factor [1]. Pregnancy 
and OC use represent transient risk factors for thrombosis and they are not necessarily associ-
ated with a higher risk for recurrence [17].
Hormonal abnormalities may also interfere with normal coagulation mechanisms in males. 
Supporting these statement, we mention the reported case of a young healthy man who 
develop extensive dural sinuses thrombosis after taking intramuscular injections of andro-
gens for body building [20, 36].
In the ISCVT, cancers account for 7.4% of all CVTs [16]. Mechanisms associated with CVT in 
cancer patients include: direct tumor compression, tumor invasion of cerebral sinuses, leu-
kostasis, the hypercoagulable state caused by increase in acute-phase reactants or altered 
coagulation factors from therapy (chemotherapeutic and hormonal agents).The most frequent 
cancers linked with CVT are the hematologic malignancies, breast tumors, nephroblastoma, 
Ewing’s tumor, gallbladder carcinoma, medulloblastoma and medullary carcinoma of the 
thyroid [14, 20].
Hematologic disorders. Philadelphia-negative myeloproliferative disorders (MPDs), especially 
polycythemia vera (PV) and essential thrombocythemia, are associated with a high risk of 
venous thrombosis, CVT being reported as a complication of these conditions in 2.8% of the 
ISCVT cases. The acquired Janus kinase 2 V617F mutation (JAK2 V617F) has been found in 
more than 90% of patients with PV and in about 50% of those with essential thrombocythe-
mia. The presence of JAK2 V617F is associated with an increased incidence of major throm-
bosis and a poor prognosis. This mutation has been also identified in patients with venous 
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thrombosis occurring in up to 15 years before diagnosis of overt MPD [37]. Other hematologi-
cal conditions can determine or predispose to venous occlusion and among them we mention: 
myelofibrosis, myeloid metaplasia, gammopathies, paroxysmal nocturnal hemoglobinuria, 
iron deficiency anemia, heparin-induced thrombocytopenia and thrombotic thrombocytope-
nic purpura [14].
Vasculitides. Numerous systemic autoimmune disorders has been associated with CVT: 
inflammatory bowel disease, systemic lupus erythematosus (SLE), with or without nephrotic 
syndrome, Behçet’s disease, Sjögren’s syndrome, Wegener’s granulomatosis, sarcoidosis, 
Hughes-Stovin syndrome, malignant atrophic papulosis [1, 4, 14].
Local causes such as head trauma, brain tumors, porencephaly, arachnoid cysts or arteriove-
nous malformations, and mechanical factors including cranial and systemic surgery, epidural 
blood patch, spontaneous intracranial hypotension, jugular venous cannulation and lumbar 
puncture can also determine dural sinus and cerebral venous occlusions [1, 4, 14, 20].
Other conditions have been associated with CVT in case reports or small series including 
severe dehydration (mostly in children and elderly), malnutrition, cardiac failure, and chronic 
obstructive pulmonary disease [5, 16, 20].
There is still a significant number of idiopathic CVT cases. According to ISCVT results, in 
almost 13% of adult CVT patients extensive search reveals no underlying cause. We also want 
to emphasize that among these patients, in 37% of those over 65 years no risk factors could 
be identified [16].
5. Pathophysiology
The venous system of the brain is a complex three-dimensional structure that is often asym-
metric, having a significantly more variable pattern than the arterial anatomy (Figure 2). The 
cerebral vasculature plays a major role in maintaining the local physiological hemodynamic 
course in order to meet the metabolic needs of the brain. Based on principles of physics 
applied to intracranial contents, within the closed skull, the sum of brain volume plus cerebral 
spine flow (CSF), plus cerebral blood volume always remains constant and, consequently, an 
increase in one of these parameters should cause a reduction in one or both of the remaining 
two. Therefore, the permeability of the vascular bed is essential in order to preserve the cere-
bral compliance [38, 39].
The cerebral blood drainage depends on the gradient between venous pressure and intra-
cranial pressure. Also for tissue perfusion to occur, the blood pressure in the feeding artery 
must exceed the pressure in the tissue and draining veins. Another pressure difference, the 
one between CSF and SSS, maintains the CSF absorption across the arachnoid villi into the 
SSS [6, 20, 39].
CVT is a multistep process that usually begins when thrombus partially occludes a dural 
sinus. In situ thrombus formation occurs due to the usual pathogenic factors – activation 
of the coagulation system and blood hypercoagulability [1, 3, 20]. The vessel wall is usu-
ally normal. The thrombosis may progresses, obstructing first the sinus and then the smaller 
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venous tributaries. The distribution of the possible consecutive lesions depends on a variable 
balance between prothrombotic and thrombolytic processes and compensation of occlusions 
by collateral circulation. Symptoms usually appear when this compensatory mechanism is no 
longer effective [3, 9, 39].
The two major pathophysiological mechanisms responsible for the clinical manifestations of 
CVT are: (1) increasing of venular and capillary pressure, and (2) decreasing of CSF absorption [4].
1. Thrombosis of cerebral veins or sinuses causes a progressive increase of venular and capil-
lary pressure.
In the early stages of venous obstruction, the extensive collateral circulation within the 
cerebral venous system provides a significant degree of compensation. Therefore, an ad-
equate perfusion of the affected brain tissue might still be possible at lower flow rates, if 
the blood is effectively drained through collateral pathways and the pathological pressure 
changes are thus, neutralized. As a result, large areas of the brain can be functionally and 
metabolically impaired, but not irreversibly damaged [6, 39].
However, prolonged intravenous hypertension corroborated with a poor collateral flow 
will result in extension of the thrombosis within cortical venous tributaries, lowering even 
more the cerebral perfusion pressure [39], which will lead to:
a. local ischemic injury and cytotoxic edema,
b. disruption of the blood–brain barrier leading to vasogenic edema, and.
c. venous and capillary rupture culminating in parenchymal hemorrhage and, less frequent, 
subarachnoid hemorrhages [4].
In milder cases, dural sinuses thrombosis may cause only an increase in intracranial ve-
nous or CSF pressure with minimal symptoms like headache or papilledema, or can remain 
Figure 2. Diagram of meningeal-cortical relationships [8].
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completely latent. Usually, the occlusion of cerebral veins is the one that leads to so-called 
venous infarct. The most common anatomic presentation is that of extensive bilateral hem-
orrhagic infarcts, located in the superior and internal parts of both hemispheres, due to 
thrombosis of the SSS and its tributary cortical veins [1, 6]. The limited drainage that occurs 
due to CVT and resulting increased venous pressure, often causes fluid to back up into the 
brain, causing vasogenic edema. This type of edema accumulates within the extracellular 
space of the cerebral and cerebellar white matter under the influence of hydrostatic pres-
sure (increased blood pressure and blood flow) and osmotic gradients. Vasogenic edema 
does not necessarily imply neuronal injury, considering that the fluid in the extracellular 
compartment can potentially be removed. On the other hand, cytotoxic edema is caused by 
energy failure with movement of ions and water across the cell membranes into cells. The 
intracellular edema, as a consequence of ischemia, is associated with the presence of a large 
volume of dead or dying brain cells and implies a bad outcome [20]. In venous infarcts, the 
vasogenic edema is much more prominent that the cytotoxic type as has been also proven 
by diffusion-weighted imaging which sustains the fact that the venous infarcts are differ-
ent from arterial ones and explains, at least partly, the much better recovery reported in 
those with CVT [1, 19]. Brain edema and increased intracranial pressure cause headache, 
decreased consciousness and vomiting, but the most important concerns related to these 
pathological processes are the pressure shifts and the risk for brain herniation which can 
be life-threatening due to possible pressure-related damage to adjacent tissues [20]. The 
raised venous and capillary pressure also determines the occurrence of vessel damages 
and erythrocytes diapedesis through the blood–brain barrier disruptions, both resulting in 
brain hemorrhage. However, the neuronal damage associated with CVT-induced hemor-
rhage is often less severe than the lesions caused by arterial ischemia [20, 39].
2. Cerebrospinal fluid is normally absorbed through arachnoids granulations especially into 
the SSS and LS. Another effect of cerebral sinuses occlusion, especially of the SSS and LS is 
the decreasing of CSF absorption which, ultimately raises the intracranial pressure. Conse-
quently, increased intracranial pressure worsens venular and capillary hypertension and 
contributes further to parenchymal hemorrhage and edema [4, 6].
Histological analysis in CVT patients reveals dilated and congestionated veins, brain edema 
with flattened gyri, obliterated sulci and compressed ventricles, ischemic neuronal damage. 
The thrombus is like other venous thrombi (rich in red blood cells and fibrin and poor in 
platelets-when it is fresh; and replaced by fibrous tissue, sometimes with recanalization-when 
it is old) [1, 6, 9, 20].
6. Clinical presentation
CVT present with a wide spectrum of symptoms, signs and modes of onset. Usually, 
these conditions are characterized by a gradual or stepwise development of symptoms. 
Thus, in 50–80% of cases the onset is subacute (over 48 h, but under 30 days); in a third 
of the patients the onset is acute (under 48 h), and in 7%, chronic (over 30 days). Besides 
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puerperal and infectious cases which tend to present acutely, the progressive increase in 
symptoms and fluctuating course are the rule in patients with other causes of venous 
occlusion. The gradual onset of CVT’ symptoms can be explain by the slow evolution 
and propagation of thrombosis and the potentially broad collateralization which may be 
able to maintain for a while an adequate drainage of cerebral blood [1, 5, 16, 20].
In patients with altered mental status associated with focal neurological deficits, seizures and 
headaches, CVT always must be considered a possible diagnosis. On the other hand, there 
were reported cases with atypical presentation and occasionally, isolated symptoms such are 
headache, a single seizure or nonspecific behavioral symptoms. In young children and espe-
cially neonates, CVT have a mostly nonspecific clinical presentation with seizures, respiratory 
distress syndrome, hypertonia, lethargy or coma [5, 9].
The clinical features of CVT depend on the following factors: gender and age of the patient, interval 
from onset to admission to hospital, site and number of thrombosed sinuses and veins and presence of 
parenchymal lesions [5, 9, 19].
The most common syndromes of CVT are: isolated intracranial hypertension, focal neuro-
logical deficits, seizures, and subacute encephalopathy. Depending on the extent and location 
of cerebral venous occlusion, these syndromes may be found in combination or as isolated 
groups of symptoms.
1. Isolated intracranial hypertension is the most homogeneous clinical pattern found in CVT 
(40%). It is characterized by headache with or without vomiting, papilledema and sixth 
nerve palsy [1, 4, 5, 20].
Headache is an extremely common symptom in patients with CVT, being present in almost 
90% of patients in the ISCVT [14–16, 20]. It is the earliest symptom in 2/3 of cases. It is also 
important to mention that headache is much more common in patients with venous throm-
boses than in patients with cerebrovascular ischemic arterial disease [6, 20]. The presence 
of this symptom in CVT cases can be explained by the increased intracranial pressure and 
the local inflammatory reaction which activates pain-sensitive fibers existing in the walls 
of the occluded sinuses, dura and overlying skull [14, 19, 20]. The headache associated 
with CVT is mostly gradual in onset, diffuse, severe in intensity, progressive and perma-
nent; it may worsen with Valsalva maneuvers or position change [1, 9, 40]. Its features can 
be misleading, mimicking migraine or the typical thunderclap headache of subarachnoid 
hemorrhage; in puerperal cases, it can be misdiagnosed as post-dural puncture headaches. 
Nevertheless, it is almost every time accompanied by other neurologic signs [1, 14, 34]. 
However, isolated headache without focal neurological findings or papilledema occurs in 
up to 25% of patients with CVT, being typically associated with LS thrombosis [6, 14, 19].
Papilledema occurs in about 25–40% of patients with CVT; it can cause transient visual impair-
ment, and if prolonged, optic atrophy and blindness. Visual loss is usually insidious, with pro-
gressive constriction of the visual fields and relative sparing of central visual acuity. Delayed 
diagnosis may expose the patient to an increased risk of later visual deficit [6, 14]. Transient 
loss of vision can occur in association with spells of intense headache and papilledema [5].
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2. Focal neurological deficits are inaugural in 15% of cases and are present in about half of pa-
tients with dural sinus and cerebral veins occlusions during the course of the disease [1]. Fo-
cal cerebral signs include central motor and sensory deficits, aphasia or hemianopia and are 
consequences of focal parenchymal abnormalities [9, 15, 20]. Unilateral or, less frequently, 
bilateral motor deficits are the most common focal findings and may be present in up to 40% 
of patients. Among this signs, hemiparesis is probably the most common. Sensory deficits 
are less frequent. Other possible symptoms associated with CVT are aphasia (usually in left 
LS thrombosis), hemianopia and ataxia (found in posterior dural sinuses occlusion) [4, 5, 20].
3. Seizures (focal, generalized or even status epilepticus) are the inaugural symptom of CVT 
in about 12–15% of cases and are present at some point during the disease in about 40% 
of patients with an even higher incidence in peripartum (76%) and neonates (71%). Par-
ticular attention should be paid to pre-eclamptic patients with CVT that develop seizures, 
considering that in these cases the diagnosis can be delayed until the empirical treatment 
for eclampsia fails to resolve the seizures [1, 4, 20, 34] Seizures are about equally divided 
between focal and generalized types, and the association of both types is common [1]. It 
is important to know that seizures are more frequently seen in CVT than in other stroke 
types [4, 5, 15]. According to numerous studies, a higher risk for inaugural and early sei-
zures was found in patients with supratentorial parenchymal lesions (especially anterior 
to the central sulcus), intracranial hemorrhage, SSS and cortical veins thrombosis (which 
drain venous blood from the motor and sensory cortices), and in those who have motor or 
sensory deficits [4, 19, 41–44]. Also, the patients with presenting seizures are considered to 
have a higher risk of early seizures. On the other hand, the risk of early seizures in patients 
without supratentorial parenchymal lesions or presenting seizures was very low. Also, the 
antiepileptic drug (AED) prophylaxis significantly decreased the risk of early seizures in 
CVT patients presenting the predisposing factors listed above [41].
4. Subacute encephalopathy-manifested mostly as a depressed level of consciousness (varying 
from drowsiness to deep coma) is present in about half of cerebral venous disease cases 
and is found in patients which are often either very old or very young [1, 4]. Alteration of 
consciousness is usually a late one, but it can be found in about 15% of patients with CVT 
at hospital admission [1, 15]. It may occur when CVT is a terminal event during another 
severe condition, or as a result of extensive acute CVT with large venous infarcts and bilat-
eral thalamic involvement, cerebral edema, or parenchymal hemorrhages that cause brain 
herniation. In CVT the alteration in level of consciousness is mostly reversible, however, 
coma at admission remains the strongest predictor of a poor outcome [20, 15]. The dif-
ferential diagnosis of CVT encephalopathy includes encephalitis, disseminated intravas-
cular coagulation and cerebral vasculitis [1]. Psychiatric disturbances (irritability, anxiety, 
depression, delirium) in association with CVT are relatively infrequent (6%) and may be 
confused to postpartum psychosis [1, 9].
The clinical pictures of CVT differ according to the location of the occluded sinus or vein, 
however, in approximately two thirds of patients thrombosis affects multiple veins or sinuses 
[1, 5, 20, 45]. The two most frequent sites of thrombosis are the SSS (62–80%) and the LS 
(38–86%). The isolated involvement of one sinus occurs in a minority of cases: less than 30% 
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for SSS and 10% for LS [1, 16, 45]. Cerebral veins are often involved but almost never in isola-
tion. Thrombosis of the galenic system is rare. It is important to know that the management 
of CVT it is not influenced by the topographic diagnosis [1, 20].
Superior sagittal sinus (SSS) thrombosis is the most commonly affected and is the favorite loca-
tion for thrombosis during the puerperium. The usual presentation of the isolated SSS occlu-
sion is that of an isolated intracranial hypertension. Symptoms and signs depend on the 
involvement of cerebral veins and other dural sinuses, especially LSs. Extension to cortical 
veins is followed by the onset of a focal motor or sensory deficit (more marked in the leg), 
focal or generalized seizures. Bilateral motor signs may also occur as a consequence of the bi-
hemispheric injuries caused by the SSS thrombosis [1, 14, 20].
Lateral sinus (LS) thrombosis has variable presentation. Patients with isolated thrombosis of LS 
usually present a pseudo tumor syndrome (isolated intracranial hypertension) [1, 19, 20]. The 
infectious etiology is much more common in LS thrombosis than in SSS occlusion. Isolated LS 
thrombosis has mostly been reported in otologic patients as a consequence of ear and mastoid 
infections, hence the term “otitic hydrocephalus” [20, 45]. The symptoms related to an under-
lying otic infections in patients with LS thrombosis are relatively characteristic. Fever, head-
ache, neck pain and neck tenderness, vertigo, nausea and vomiting, diplopia caused by sixth 
nerve palsy and signs of fifth nerve irritation manifested as temporal and retro-orbital pain are 
often present. The mastoid region may be sensitive to finger percussion. Decreased alertness 
may occur [14, 20]. Intracranial hypertension is more common after right-sided LS throm-
bosis because the left LS is often hypoplasic; in these patients right LS occlusion will cause a 
bilateral drainage impairment, affecting structures on either side of the tentorium, especially 
the inferior portions of the temporal lobe and cerebellum. Therefore, combined temporal lobe 
and cerebellar signs on one side suggest LS thrombosis [20]. Fluent aphasia, is common in left 
transverse sinus thrombosis (40%) and can be accompanied by right hemianopia or superior 
quadrantanopia. Right temporal lobe involvement causes an agitated state and left visual field 
defect. Nystagmus and gait ataxia are the typical signs of cerebellar involvement [4, 5, 20]. The 
thrombotic process spreads, in most of the cases, to other sinuses and veins, especially to the 
SSS. Focal signs are present when thrombosis extends to superior or inferior petrosal sinuses 
(5th and 6th cranial nerves involvement), SS and deep venous system, adjacent cortical veins 
and the jugular bulb (9th, 10th and 11th cranial nerves involvement) [1, 5]. In rare cases, a 
patient with thrombosis limited to the left LS (without involvement of tributary veins), pres-
ents an atypical clinical picture (migraine-like acute isolated headache), and the thrombosis is 
not due to an ear infection, but to a thrombophilia [4, 46]. In consequence, we have to system-
atically look for LS thrombosis (and other CVT) in patients with recent headache even in the 
absence of associated symptoms and signs, and ear infections.
Cavernous sinus thrombosis usually has an infectious cause. The most common germs impli-
cated in septic cavernous sinus thromboses are staphylococcus, streptococcus and pneumo-
coccus [20, 47]. Cavernous sinus thrombosis represents the single CVT which produces a 
characteristic clinical syndrome which includes: chemosis, conjunctival edema, proptosis and 
painful complete or partial ophthalmoplegia [1, 5, 9, 20]. Papilledema is common and may be 
associated with hemorrhages of the retina. Symptoms generally start in one eye, but within a 
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couple of days the other eye is usually affected via intercavernous sinuses. Headache, facial 
pain and fever can precede the typical syndrome described [9, 20]. The direct relationship 
between the cavernous sinus and the dura results in symptoms of meningeal irritation. When 
the occlusion extends to other sinuses and cortical veins, seizures and motor weakness may 
occur [9, 47]. Head trauma, surgery on intracranial or facial structures, prothrombotic states 
and thrombosis of dural arteriovenous fistulas can result in aseptic cavernous sinus throm-
bosis. The signs and symptoms of this disease take a more indolent form with an isolated 
abducens nerve palsy and mild chemosis and proptosis [1, 20, 47].
Thrombosis of the superior and inferior petrosal sinuses is usually a sequela of cavernous or 
LS thrombosis. The occlusion of the superior sinus presents as a trigeminal palsy, while the 
thrombosis of the inferior one is characterized by an abducens palsy [1].
Cortical veins thrombosis. Isolated thrombosis of cortical veins without associated dural sinus 
occlusion is infrequent (2%) [1, 20]. The most often involved are the superior cerebral veins 
(rolandic, parieto-occipital and posterior temporal) which empty into the SSS. This condition 
presents as focal deficits or seizures of sudden or progressive onset. However, if the collateral 
circulation is efficient there will be only an area of localized edema (that can be asymptomatic) 
or no parenchymal lesion at all. The neuronal lesions that may appear are mostly reversible, 
thus the clinical recovery is complete in some cases. Usually, thrombosis spreads to the SSS 
and to cortical veins on the opposite side, leading to signs of intracranial pressure and bilat-
eral parasagittal infarct [1].
Thrombosis of the deep venous system is more frequent in children; it is much less common than 
dural sinus thrombosis. This condition can cause extensive thalamic and basal ganglia hemor-
rhagic infarcts and edema, sometimes with bilateral brain involvement [14, 20]. The clinical pic-
ture is usually severe. Most patients present with rapid neurological deterioration, manifested 
as stupor or coma, decerebration, decortication, signs of raised intracranial pressure, papillary 
changes, vertical gaze palsy, mental troubles, and motor deficits [1, 14, 19, 20]. The most com-
mon symptoms in adults are headache, nausea and vomiting, gait ataxia, neuropsychological 
symptoms, disturbances of consciousness, hemiparesis (that may be bilateral or alternating) 
and seizures. When patients survive, they often show residual signs such as abulia or memory 
impairment. It was reported the possibility of benign forms of galenic thrombosis [1, 20].
Venous infarctions in the posterior fossa result from thrombosis of LS, SS and the superior petro-
sal vein. The isolated form is extremely rare due to the abundant collateral venous drainage of 
the posterior structures. However, it is an important differential diagnosis in patients who has 
risk factors for CVT and presents with cerebellovestibular symptoms, headache, intracranial 
hypertension syndrome, and atypical findings on brain CT such as pan-cerebellar and verm-
ian infarcts, cerebellar hemorrhages of irregular shapes, or with extension to the subarachnoid 
space and cerebellar peduncles [48]. Cerebellar veins thrombosis causing cerebellar infarction 
has only rarely been described. This condition is usually associated with LS thrombosis. The 
clinical pictures of venous and arterial cerebellar infarcts are similar, the most common signs 
being headache, vomiting, ataxia and unilateral dysmetria; these symptoms can be associated 
with a decrease in conscious level and papilledema suggesting obstructive hydrocephalus. If 
the thrombotic process spreads to IJV, the patients may develop cranial nerve palsies (9th and 
10th cranial nerves involvement) [1, 20].
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Internal jugular vein (IJV) thrombosis is, in most of the cases, a consequence of LS thrombosis 
extension, presenting with unilateral pulsating tinnitus or multiple cranial nerve palsies. IJV 
thrombosis can be rarely, accompanied by pulmonary embolism. The thrombophlebitis of the 
jugular vein may occur as a complication of the syndrome of tonsillopharyngitis (Lemierre’s 
syndrome) [1, 9, 20].
The emissary veins (EV) (e.g. petrosquamosal sinus (PSS)), are residual valveless veins which 
connect the intracranial dural venous sinuses and the extracranial venous system. Posterior 
fossa EVs go through cranial apertures and participate in extracranial venous drainage of the 
posterior fossa venous system, in addition to IJV. EVs are usually small and have no clinical 
significance in healthy people; however they may become enlarged in patients with high-flow 
vascular malformations, IJV aplasia or thrombosis. In such cases, the clinical picture may 
include various craniofacial syndromes and tinnitus [49, 50].
7. Diagnosis
The diagnosis of CVT is typically based on clinical suspicion and imaging confirmation – dem-
onstration of an occluded sinus/vein and of the thrombus [2, 14]. Patients with CVT are younger, 
usually female and have low frequencies of vascular risk factors (hypertension, coronary artery 
disease, diabetes and smoking) when compared with patients with arterial occlusive disease 
[20]. The clinical evolution in CVT patients is slower than in those with arterial occlusion and 
is characterized by headache and other signs of intracranial hypertension associated with focal 
neurological deficits and new seizures. The presence of hemorrhagic infarcts, especially if mul-
tiple or in no arterial vascular territories also indicates CVT [4, 20]. The highly variable clinical 
picture of cerebral venous disease often cause important delays in diagnosis [4].
8. Laboratory testing: thrombophilia testing
In order to establish the underlying cause of cerebral venous disease, there may be necessary 
several laboratory investigations [1].
Blood assay. A complete blood count, chemistry panel, sedimentation rate, measures of the 
prothrombin time and activated partial thromboplastin time are indicated for patients with 
suspected CVT. These tests may demonstrate abnormalities suggestive of a hypercoagulable 
state, infective, inflammatory or malignant disorders. (Class I; Level of Evidence C). A urinaly-
sis may reveal proteinuria indicating a nephrotic syndrome. Considering that in elderly CVT 
patients, the proportion of cases with malignancies and hematological disorders is higher and 
that, sometimes, the cause of CVT is revealed only weeks or months after the acute phase, 
searching for an occult neoplasm is always recommended in elderly patients and idiopathic 
cases [1, 2, 14].
D-dimer concentrations are increased in most patients so a low level of D-dimer (<500 ng/mL) 
may help identify patients with low probability of CVT (Class IIb; Level of Evidence B). It is 
important to mention that normal D-dimer level does not exclude the diagnosis, particularly 
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in patients who present with isolated headache and in case of prolonged duration of symp-
toms (i.e. >1 week) before the test [4, 14, 20, 51].
Lumbar Puncture is indicated only if there is a clinical suspicion of meningitis. Elevated open-
ing pressure is a frequent finding in CVT and is present in about 80% of patients. Also, there 
may be observed a mild lymphocytic pleocytosis, increased protein and red blood cells. The 
CSF is rarely (10%) entirely normal in CVT, but there are no specific CSF abnormalities associ-
ated with this condition [1, 9, 14].
Thrombophilia screening is recommended in all CVT patients, especially in those with high 
probability of carrying severe thrombophilia (i.e. a personal and/or family history of venous 
thrombosis, young age at CVT, CVT without a transient or permanent risk factor) [4, 14]; 
these tests should be performed even when another associated condition is already found 
because they imply a systematic family study and modify the long term management of the 
patients. Testing for prothrombotic conditions should include evaluation for prothrombin 
G20210A mutation, factor V Leiden mutation, protein C, protein S, antithrombin deficiency, 
antiphospholipid syndrome (lupus anticoagulant, anticardiolipin antibodies), and hyperho-
mocysteinemia. Testing for protein C, protein S, and antithrombin deficiency must be per-
formed at least 6 weeks after a thrombotic event and 2–4 weeks after stopping warfarin. (IIa/ B) 
[2, 4, 14]. Protein C, S, and antithrombin levels may be also influenced by oral contraceptives, 
pregnancy, severe liver disease, L-asparaginase chemotherapy and nephrotic syndrome. The 
screening results should be confirmed with repeat testing and family studies [2, 4]. Other tests 
may include a functional plasminogen assay and qualitative testing of platelet functioning.
A diagnosis of antiphospholipid syndrome requires abnormal laboratory testing on 2 or more 
occasions at least 12 weeks apart because abnormal results may occur transiently due to the dis-
ease process, infection, some medications or other causes. However, if a normal result is obtain 
at the time of clinical presentation, the antiphospholipid antibody syndrome is ruled out [14].
9. Imaging
The diagnosis of CVT is based on neuroimaging. The goal of this tests is to determine vascular 
and parenchymal changes associated with this condition (Figure 3) [14, 19].
Computed tomography is usually the first investigation performed in patients who present 
with new-onset neurological symptoms such as headache, seizure, mental alteration, or focal 
neurological signs [5, 14]. It is useful especially in the emergency setting because is fast and 
widely available [2, 52]. The place of CT scanning in the diagnostic strategy of CVT is mainly 
the rule out other acute cerebral disorders that CVT can imitate including arterial stroke, 
abscess, tumors and subarachnoid hemorrhage. Sometimes, CT identifies lesions that can 
themselves cause CVT such as meningioma, abscesses, sinusitis or mastoiditis [1, 4, 5].
There have been described various direct and indirect CT signs associated with CVT.
a. Direct signs of CVT can be founded in about 1/3 of CVT cases; they correspond to the visu-
alization of thrombus itself and include: the “cord sign, the “dense triangle sign,” and the 
“empty delta sign.” [5, 6, 14]
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The cord sign (visible on unenhanced CT scans) is found in 25% of CVT patients and is defined 
as a homogeneous hyperdense appearance of a thrombosed cortical or deep vein. It reflects 
a newly formed thrombus in a cerebral vein and is best seen within the first week of the dis-
ease. After 7–14 days, the clot becomes isodense and then hypodense. It is known that slow 
flow can also produce this sign, thus its specificity is considered to be rather low [1, 6, 52].
The “dense triangle sign” (seen on no contrast CT scans) was reported in less than 2% of cas-
es; it is characterized by the hyperdense appearance of the thrombosed sinus and can be 
seen during the first 2 weeks of the disease. Mimicking occurs in patients with increased 
hematocrit or dehydrated [1, 3, 6, 9].
The empty delta sign (seen after injection of contrast agent) is present in about 35% of re-
ported cases and only in patients with SSS thrombosis. The empty delta sign reflects a lack 
of contrast enhancement within the posterior 1/3 of the SSS that is surrounded by contrast 
enhancement of the wall of the sinus due to the presence of collateral tributaries. It is ab-
sent when the test is performed either in the first 5 days or more than 2 months after onset 
of symptoms. An early division of the SSS can appear as a false delta sign [1–5, 20].
b. Indirect signs of CVT are more frequent and include the following findings. Intense contrast 
enhancement of the falx and tentorium or areas of gyral enhancement can be observed in 
Figure 3. (A) Nonenhanced computed tomography (CT) in the axial plane demonstrating spontaneous hyperdensity of 
the left lateral sinus (white arrow). (B) Magnetic resonance (MR) T2*SW imaging in the axial plane demonstrating left LS 
hyposignal (white arrow). (C) Magnetic resonance (MR) venography in the coronal plane noting absence of flow in the 
left LS (thrombosis of the left LS) (white arrow) [46].
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the region of a thrombosed dural sinus; it is seen in 20% of CVT cases [1, 5, 20]. The pres-
ence of brain edema with small, compressed ventricles can be found in 20–50% of CVT 
patients. This sign can be difficult to differentiate from normal brain, especially in young 
patients. The opposite finding (enlarged ventricles) does not exclude the diagnosis con-
sidering that it can be associated with cerebellar vein thrombosis [1, 20]. Cortical veins 
may appear dilated on contrast-enhanced scans due to dilatation of collateral tributaries 
[20]. Localized or diffuse areas of white matter hypodensity without contrast enhancement 
are present about 75% of cases; they suggests cerebral edema (sometimes associated with 
mass effect) or venous infarction which usually do not respects the arterial boundaries. 
Venous infarcts can be unilateral or bilateral, single or multiple; venous infarcts are usually 
hemorrhagic, being described on CT as spontaneous hyperdensity (10–50%); In most CVT 
patients, parenchymal lesions manifests on CT as large subcortical often multifocal hema-
tomas and petechial hemorrhages within large hypodensities. No hemorrhagic venous in-
farcts are considered to be equally frequent. In serial CT scans some lesions may disappear 
(“vanishing infarcts”) and new others may appear [1, 5, 20]. In less than 1% of cases, CVT 
is associated with a subarachnoid hemorrhage, usually found in the vicinity of the venous 
occlusion. Subdural hematomas are also infrequent [1, 2, 14, 20].
Particular forms of CVT may present with some distinctive features. On post-contrast CT 
scans of patients with cavernous sinus thrombosis can be found multiple irregular filling 
defects with bulging cavernous sinuses and enlarged orbital veins. Cerebellar venous infarc-
tion can be associated with hydrocephalus and compression of the forth ventricle. In case 
of deep venous system thrombosis the characteristic findings may include: the presence of 
bilateral hypodensities involving the thalami and basal ganglia, hyperdensities in these same 
regions (hemorrhages or hemorrhagic infarction), severe edema with compression of the 
third ventricle and hyperdense appearance of the occluded sinuses and deep veins on unen-
hanced CT scans [1, 20].
It is important to emphasize that CT is normal in up to 30% of CVT cases and most of the find-
ings are nonspecific. Anatomic variability of the cerebral venous system makes CT diagnosis 
of CVT insensitive, results on no contrast head CT being abnormal only in 30% of CVT cases. 
Therefore, a negative CT examination will not exclude a diagnosis of CVT; in suspected cases, 
an MRI or angiographic examination is necessary for further confirmation [4, 5, 14, 53].
Nevertheless, the distribution of the parenchymal abnormalities, including diffuse edema, 
bilaterally infarcts or hemorrhages, predominance of hemorrhagic changes and the presence 
of a lesion which crosses usual arterial boundaries should always raise the suspicion of CVT 
[14, 20].
CT angiography (helical CT venography) with bolus injection of contrast material gives excel-
lent details of venous circulation anatomy and pathological changes including: filling defects 
in the occluded sinus or veins, sinus wall enhancement, increased collateral venous drainage 
and tentorial enhancement [1, 5]. CT venography is especially useful in the acute setting 
because it provides a rapid (it can be performed immediately after brain CT) and reliable 
method for detection of CVT, particularly in patients with contraindications to MRI. Also, 
it allows the diagnosis of sub-acute or chronic CVT because it can detect thrombus of 
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heterogeneous density. CT venography is less invasive, less expensive and offers a better 
visualization of the cavernous and inferior sagittal sinuses then intra-arterial angiogra-
phy; it is comparable to MR venography for the diagnosis of cerebral venous thrombosis. 
Limitations of CT venography include: limited visualization of skull base structures in 3D 
display, contrast allergy, contrast nephropathy and radiation exposure, which may limit its 
use in pregnant women, children and patients with renal failure [4, 5].
Magnetic resonance imaging. The combination of MRI showing the thrombosed vessel and 
MR venography (MRV) demonstrating the no visualization of the same vessel is currently 
the most sensitive (90%) method to confirm the diagnosis of CVT in the acute, subacute, and 
chronic phases. Therefore, the combination of an alteration of signal intensity in a dural sinus 
and a corresponding absence of flow on MRV supports the diagnosis of CVT [2, 4, 14, 53, 54].
MRI pathological signs in patients with CVT include those seen in the venous channels and 
those seen in the brain parenchyma [14].
The signal intensity of the thrombus on T1- and T2-weighted MR images varies according to the 
age of the thrombus [5, 6, 14]. In the acute stage (0–5 days), flow void is absent and the occluded 
vessel appears isointense with brain parenchyma on T1-weighted and hypointense on T2, due 
to the appearance of deoxyhemoglobin in red cells within the thrombus. In the sub-acute phase 
(6–15 days), the absence of flow void persists, but, the thrombus appears hyperintense in both 
T1- and T2-weight images due to the accumulation of methemoglobin in the venous throm-
bus. These intermediate pattern (increased signal on T1- and T2-weighted images) is charac-
teristic for CVT. In chronic stages, recanalization of the previously occluded vessel results in 
reappearance of the flow void; the thrombus can be heterogeneous with variable intensity on 
T2-weighted and isointense on T1-weighted images, related with the presence of the deoxygen-
ated hemoglobin and methemoglobin products. At 6 months, more than 2/3 of cases still show 
some heterogeneous localized signal abnormalities which can persist for years [1, 4, 53, 54].
MRI shows a variety of focal parenchymal changes in up to 40% of patients; they include: 
edema, brain swelling and/or hemorrhage. The presence of edema is suggested by increased 
signal on T2-weighted images and isointense or hypointense signal on T1- weighted images. 
An increased signal in both T1- and T2-weighted images is indicative for parenchymal hemor-
rhage and can be seen in about 30% of the CVT cases [1, 6, 14, 53].
The SSS thrombosis is typically associated with flame-shaped, irregular areas of lobar hemor-
rhage in the parasagittal frontal and parietal lobes; temporal or occipital lobe parenchymal 
changes correspond to lateral (transverse and sigmoid) sinus thrombosis; deep parenchymal 
abnormalities, including thalamic hemorrhage, edema, or intraventricular hemorrhage are 
suggestive for thrombosis of the vein of Galen or SS [6, 14].
After contrast (gadolinium) administration, marked contrast enhancement and flow voids 
may be observed within the thrombosed sinuses, slow flow in dural and intrathrombus col-
lateral channels or recanalization [2, 5].
Diffusion-weighted imaging (DWI) allows the direct visualization of the clot as a high signal 
intensity within the affected vein or dural sinus. However, the major interest of DWI is to 
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show, in the venous infarcts, a diffusion pattern significantly different from that in arterial 
infarcts. The DWI most common pattern of brain lesions in CVT is a heterogeneous signal 
intensity with normal or increased apparent diffusion coefficient (ADC) corresponding to 
vasogenic edema, and thus, markedly different from that of arterial infarcts [1, 5, 19].
Echo-planar T2 susceptibility weighted imaging (T2*SW) sequences are useful in the diagnosis of 
isolated cortical venous thrombosis and during the very early days of acute CVT when T1 
and T2 are less sensitive. This diagnosis technique identifies the intraluminal thrombus as a 
hypointense area [2, 5, 19].
Hydrogen 1 magnetic resonance spectroscopy (MRS) shows a normal N-acetyl aspartate (NNA) 
peak and a small lactate peak, suggesting that the functionally impaired neurons are still viable 
in CVT; these findings also, emphasize the difference between venous and arterial infarcts [1].
The MRI advantages in CVT diagnosis include sensitivity to blood flow, ability to visualize 
the thrombus itself and noninvasiveness. However, its use is limited in some situations, such 
as comatose patients or in dubious cases (e.g. isolated cortical vein thrombosis), when intra-
arterial angiography is necessary to confirm the diagnosis [1, 5].
Magnetic resonance venography (MRV) has become the imaging modality most widely used 
in CVT diagnosis, being easily repeatable and noninvasive [1, 3, 20]. Several methods can 
assess venous or dural sinus flow: two-dimensional time-of-flight (2D-TOF), three dimen-
sional time-of-flight (3DTOF) and phase contrast; contrast enhancement MR venography with 
elliptic centric ordering is a newer technique which allows superior assessment of smaller 
venous channels [1, 5, 20]. The 2D-TOF technique is the most commonly used method for 
the diagnosis of CVT, showing abnormalities in the normal flow signals, no opacification of 
sinuses and collateral venous channels; the absence of flow signal indicates a complete intra-
luminal thrombosis [1, 14, 20]. The indirect signs of cerebral venous disease include delayed 
emptying, collateral venous pathways, venous dilation and tortuous cortical collateral veins 
(corkscrew veins) [3]. Contrast-enhanced MRV is also useful in distinguishing anatomic vari-
ants such as a hypoplasic sinus from CVT. Nevertheless, MRV has a limited role in diagnosing 
partial thrombosis, cortical vein and cavernous sinus thrombosis; also it has limited utility in 
patients with renal disease (risk of nephrogenic systemic fibrosis) [1, 3, 4]. In order to assess 
the recanalization of the occluded cortical vein/sinuses it is recommended to perform a fol-
low-up CT or MR venography at 3–6 months after diagnosis (IIa/ C) [1, 14].
Cerebral angiography and direct cerebral venography are invasive diagnostic techniques, 
being reserved for rare situations when the clinical suspicion of CVT is high, but MR or CT 
venography results are inconclusive or if an endovascular procedure is planned. For example, 
it may be useful in cases of isolated cortical vein thrombosis or when is necessary to exclude 
a dural arteriovenous fistula or distal aneurysm [4, 5, 14].
Cerebral angiography. The partial or complete lack of opacification of veins or sinuses is the 
best angiographic evidence of CVT. Other signs present and suggestive for venous occlusive 
disease are: venous congestion with dilated cortical, scalp, or facial veins, dilatation of col-
lateral venous channels (“corkscrew” veins) and reversal of venous flow [1, 14, 20]. CVT is 
easy to recognize on angiography when it affects the posterior or whole SSS, both LSs or the 
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deep venous system, but it can be confused with hypoplasia when the anterior third of the 
SSS or the left LS are occluded. In such cases, in order to establish the diagnosis of CVT is 
necessary to find additional evidences: involvement of another sinus or delayed emptying 
and dilated collateral veins in occlusion of the anterior part of the SSS and absence of filling 
of the whole sinus or its sigmoid portion in LS thrombosis. The presence of collateral veins 
pathways usually indicates SSS thrombosis and is found in about 50% of CVT cases [1]. The 
limitations of this technique include the facts that it does not show the thrombus itself, has a 
traumatic effect, is associated with the usual risk of complications during surgery, involves 
a certain amount of radiation, requires a higher technical competency and may only be per-
formed in a qualified hospital. Also, certain individuals are allergic to the iodine contrast 
material [1, 53].
Direct cerebral venography is usually performed during endovascular therapeutic procedures; 
it allows the visualization of the intraluminal thrombus either as a filling defect within the 
lumen (no occlusive thrombosis) or as complete no filling (occlusive thrombosis). Complete 
thrombosis may also present a “cupping appearance” within the sinus [14].
10. Management
The treatment of cerebral venous disease focuses on a combination of symptomatic, etio-
logic and antithrombotic medications on a case-by-case basis. The therapeutic measures 
used in clinical practice are based on anticoagulation, control of seizures, and management 
of increased intracranial pressure. Any underlying cause or risk factors should be managed 
appropriately. Patients with CVT should be admitted in a stroke unit and the treatment, 
started as early as possible [1, 9, 15].
10.1. Acute phase therapy
10.1.1. Antithrombotic treatment
There is now ample evidence that heparin is safe even when CT or MRI demonstrate a hem-
orrhagic lesion. The aims of antithrombotic treatment in CVT are to recanalize the occluded 
sinus or vein, to combat the propagation of the thrombus, and to treat the underlying pro-
thrombotic state-in order to prevent venous thrombosis in other parts of the body-and to 
prevent the recurrence of CVT [1, 5, 19].
A meta-analysis shows that, with heparin, there is an absolute risk reduction in mortality of 
14% and in death or dependency of 15%, with relative risk reduction of 70 and 56%, respec-
tively [1, 55]. In ISCVT cohort, more than 80% of the patients were treated with anticoagu-
lants, indicating a consensus on the efficacy and safety of anticoagulation in the acute phase 
of CVT [16]. Despite the fact that new or increased hemorrhages do indeed occur after heparin 
treatment for cerebral venous disease, their frequency is low. The risk for intracranial and 
systemic hemorrhages is as well, low and such hemorrhages did not influence the outcome. 
Anticoagulant therapy is also safe in children [5].
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Thus, current guidelines recommend immediate treating patients with acute CVT with hepa-
rin, as a bridge to oral anticoagulation with a vitamin K antagonist. Heparin is either subcuta-
neously administered low–molecular weight heparin (LMWH) (180 anti-factor Xa U/kg/24 h 
administrated by two subcutaneous injections daily) or dose adjusted intravenous (IV) 
unfractionated heparin (UFH), titrated to an activated partial thromboplastin time (APTT) of 
twice the upper limit of normal. This recommendation also applies to patients with an intra-
cerebral hemorrhage at baseline (Ia/A). LMWH should be preferred in uncomplicated CVST 
cases considering that LMWHs have a longer-life, more predictable clinical response and less 
interaction with platelets compared with standard heparin. However, this recommendation 
does not apply to patients with a contraindication for LMWH (e.g. renal insufficiency) or in 
cases when fast reversal of the anticoagulant effect is necessary (e.g. patients who have to 
undergo neurosurgical intervention) [2, 15, 19, 51].
Although the majority of patients recover with anticoagulant therapy, a subset of patients with 
CVT have poor outcomes despite anticoagulation. Local IV thrombolysis (catheter-directed 
fibrinolysis), with or without mechanical thrombectomy are invasive therapeutic procedures 
which have been considered only in acute patients with CVT and large hemorrhagic infarcts, 
without impending herniation, who deteriorate despite adequate anticoagulation and symp-
tomatic treatment (III/B) [1, 2, 19]. These procedures may be performed in selected expertise 
centers in interventional radiology [5, 19].
Thrombolysis can be done through peripheral veins or through selective cannulation. In direct cath-
eter thrombolysis, a microcatheter and microguide wire are sent to the occluded dural sinus 
through a guiding catheter from the jugular bulb. Mechanical manipulation of the throm-
bus with the guidewire can potentially reduce the amount of fibrinolytic agent required 
for sinus recanalization [14]. Balloon-assisted thrombolysis may be more efficient because the 
inflated balloon may reduce washout of fibrinolytic agent, thus lessening the dose used and 
the risk of its eventual side effects. The balloon may be used to perform partial thrombec-
tomy before pharmacological thrombolysis [14]. It is important to emphasize that, currently 
there is no evidence to support the routine use of thrombolysis, considering that both local 
urokinase and r-TPA carry an undeniable risk of hemorrhagic complication and may require 
continuous infusion [1, 5, 15, 56, 57].
Catheter thrombectomy. Currently there is no endovascular device specifically designed to treat 
CVT [57]. The AngioJet system, which was designed for use as a thromboaspiration catheter in 
cardiovascular indications, is not sufficiently supple to be easily passed through the tortuous 
intracranial sinuses. Although, the walls of the sinuses are thick enough to allow catheteriza-
tion, the AngioJet device should be removed after partial recanalization of the thrombosis 
and follow-up with additional local thrombolysis [14, 58, 59]. The Merci retrieval is a snare-
type device that removes thrombus in a corkscrew fashion using a series of coiled wires. 
This device may be used in combination with local thrombolysis in order to avoid damaging 
the wall or trabeculae of the dural sinus [58, 60]. The Penumbra System is a new-generation 
neuroembolectomy device helpful mainly in arterial thrombus extraction [14, 61, 62]. It uses 
a separator wire under vacuum suction in order to destroy the clot. In CVT patients, it may 
be performed in combination with continuous infusion of local urokinase [58, 63] or with an 
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adjuvant balloon angioplasty (without local thrombolysis) [58, 64]. The risks associated with 
the Penumbra System use in CVT treatment are similar to those seen with the Merci and 
AngioJet systems [14].
10.1.2. Symptomatic treatment
Early initiation of antiepileptic drugs is recommended in patients with acute CVT presenting 
a single seizure with or without supratentorial lesions, in order to prevent early recurrent sei-
zures. The routine use of antiepileptics in CVT patients without seizures is not recommended 
(III/C) [14, 19, 51]. However, antiepileptic drugs could be considered as an option for patients 
with either acute seizures, supratentorial lesions or motor deficits. Any of the major antiepi-
leptic agents can be used, however valproate is preferred to phenytoin and carbamazepine 
because it causes less interference with oral anticoagulants. If it is not tolerated other antiepi-
leptic (lamotrigine, levetiracetam) can be used [1, 5, 51].
10.1.3. Treatment of intracranial hypertension
Brain swelling is observed in about 50% of all CVT on CT scan, however minor brain edema 
needs no treatment than anticoagulants, considering that heparin improves the venous out-
flow and, thus reduce intracranial pressure in most patients. Antiedema treatment is required 
in only 20% of patients [15, 19].
General recommendations in the acute stage of CVT include: elevating the head of the bed, 
osmotic diuretics (e.g., mannitol), intensive care unit admission with sedation, hyperventilation 
to a target PaCO
2
 of 30–35 mmHg and ICP monitoring [5]. In cases associated with severe headache 
with or without papilledema, the symptoms can be ameliorate with analgesics or through a ther-
apeutic lumbar puncture (LP) (before starting heparin) when not contraindicated by parenchy-
mal lesions. Administration of a diuretic as acetazolamide or furosemide is a therapeutic option 
[1, 5]. In patients with isolated intracranial hypertension and threatened vision, a LP should be 
performed with sufficient CSF removal to obtain a normal closing pressure. Acetazolamide may 
be an option in patients with papilledema [15, 19]. If severe headaches persist or vision continues 
to deteriorate despite the correct treatment, there should be considered shunting procedures 
(lumboperitoneal, ventriculoperitoneal shunts or optic nerve fenestration) [5, 15]. If consciousness 
becomes abnormal, mannitol is usually added; however, shunting or barbiturate-induced coma 
might be necessary in more severe cases [1].
In patients with CVT and large hemorrhagic infarcts, with imminent unilateral hemispheric 
herniation, decompressive surgery, such as hemicraniectomy or hematoma evacuation can be 
life-saving, with improved clinical outcomes (III/B) [2, 4, 19].
10.1.4. Etiologic treatment
In CVT patients with a suspected local or systemic infection the treatment should include 
administration of the appropriate antibiotics and the surgical drainage of infectious sources. 
(I/C) [1, 14].
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10.2. Management after the acute phase
In order to prevent recurrent CVT and other venous thrombosis, the anticoagulation should 
be continued after the acute phase of CVT [19]. There are no controlled data on the required 
duration of oral anticoagulation. Thus, the guidelines recommend anticoagulation with an 
oral vitamin K antagonist and a target INR between 2 and 3 for 3–6 months in patients with 
provoked CVT (septic thrombosis) and 6–12 months in patients with idiopathic CVT and in 
those with “mild” thrombophilia. Patients with recurrent CVT, deep vein thrombosis, or pul-
monary embolism complicating CVT or initial CVT in the setting of “severe” thrombophilia 
(homozygosity for prothrombin gene mutation 20,210 or factor V Leiden; combined thrombo-
philias; deficiencies of antithrombin, protein C, or protein S; or antiphospholipid antibodies), 
should be considered for indefinite duration anticoagulation (III/B) [2, 4, 17, 19].
Prevention of seizures. Seizures occur in 11% of the patients, more so if the patient had seizures 
in the acute phase or had a hemorrhagic parenchymal lesion. Such patients can be placed on 
antiepileptic drugs to prevent seizure recurrence [19]. Then, anticonvulsants can be progres-
sively discontinued 1 year after CVT in patients with normal EEG and no recurrent seizures [1].
Acetazolamide might be helpful in patients with milder pressure elevation found during 
follow-up, but if visual acuity decreases and the headaches persist despite to these measures, CSF 
shunting procedures should be considered [9, 19].
It is important to know that steroids are not useful and should be avoided in patients with 
cerebral venous disease, unless they are needed to treat an underlying disease. (IIa/B). Current 
guidelines recommend using steroids in patients with acute CVT and Behcet’s disease or 
other inflammatory diseases (e.g. SLE) to improve outcome [2, 19, 51].
Contraception and future pregnancies. Anticoagulation for CVT during pregnancy and early in 
the puerperium consists of full-dose LMWH in the majority of women, considering that, in 
contrast to UFH, LMWH is not associated with teratogenicity or a higher risk of fetal bleeding 
(IIa/C) [5, 14, 17]. If there is needed, a regional anesthesia should be performed 10–12 h after 
the last prophylactic dose of LMWH and 24 h after the last therapeutic dose of LMWH. If 
there are used prophylactic UFH doses (5000 units twice daily), regional anesthesia can be 
safely placed, but in cases which require higher doses (10,000 units twice daily or greater), an 
individual assessment is usually necessary [65–67].
The anticoagulant therapy with LMWH or vitamin K antagonist with a target INR of 2.0–3.0 
should be continued for ≥6 weeks postpartum (for a total minimum duration of therapy of 
6 months) (I/C). Women who have suffered CVT in the setting of hormonal contraceptive ther-
apy should use other contraceptive methods apart from oral or parenteral agents. Emergency 
contraception and hormonal replacement therapy are also contraindicated. Women with a 
history of CVT while receiving OC, during pregnancy, or during the postpartum period have 
an increased risk of recurrence during subsequent pregnancies. Thus, prophylactic antico-
agulation with LMWH during future pregnancies and the postpartum period is reasonable 
for women with previous history of CVT (IIa/C) [4, 5, 17]. It is essential to know that CVT 
and pregnancy and puerperium-related CVT are not contraindications to future pregnancy. 
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Nevertheless, further investigations regarding the underlying cause and a consultation with 
a hematologist or maternal fetal medicine specialist are indicated. Women of fertile age with 
past CVT should be advised not to become pregnant while taking an oral anticoagulant 
because of its teratogenic effects [5, 17, 19].
11. Prognosis
The clinical course of CVT is unpredictable and the individual prognosis is difficult to pre-
dict, but the overall vital and functional prognosis of this condition is far better than that of 
arterial stroke, with about two-thirds of patients recovering without sequelae [5, 17, 19]. In 
a meta-analysis of 1180 patients with CVT, the mean 30-day mortality rate was 5.6%, that 
of death at the end of follow-up was 9.4% and that of complete recovery was 88% [4, 5, 68]. 
Approximately 4% of patients with CVT die within 30 days from symptom onset [14, 16]. The 
primary cause of death in acute CVT is transtentorial herniation secondary to a large hem-
orrhagic lesions, followed by herniation due to multiple lesions or to diffuse brain edema. 
Other causes of early death include status epilepticus, medical complications, and pulmo-
nary embolism [4, 14, 19]. A high mortality rate within the first months is associated with 
depressed consciousness, altered mental status, thrombosis of the deep venous system, right 
hemisphere hemorrhage and posterior fossa lesions [9, 14, 19].
According to ISCVT results, about 1/4 of CVT patients deteriorate after their initial presenta-
tion, developing seizures, coma, worsening of or a new focal deficit, increased headaches or 
vision loss. Among these patients, about 1/3 will have new parenchymal lesions if neuroimag-
ing is repeated [2, 9, 16].
Predictors of poor outcome derived from the ISCVT cohort are: central nervous system infec-
tions, malignancy, deep cerebral venous system thrombosis, hemorrhage at admission CT/
MRI, GCS score on admission less than 9, poor mental status, age older than 37 years and 
male gender [16, 51]. Death after the acute phase is predominantly due to the underlying 
conditions, in particular malignancies [2, 19]. Based on this results, the ISCVT study group 
developed a risk score for poor outcomes which range from 0 (lowest risk) to 9 (highest risk) 
with a cut-off ≥3 points indicating a higher risk of death or dependency at 6 months. Two 
points were assigned for the presence of malignancy, coma, or thrombosis of the deep venous 
system and 1 point for male sex, presence of decreased level of consciousness, or intracerebral 
hemorrhage (ICH) [14, 69].
If the patient with CVT survives, the prognosis for recovery is much better (about 80%) than 
for patients with arterial stroke. A minority (10%) of patients are found to have permanent 
neurological deficits by 12 months of follow-up. About 44% of the CVT patients have some 
degree of handicap or significant cognitive impairment after 1–4 years [1, 4, 16]. Sequelae 
of CVT include cognitive and motor impairments, seizures, headaches, visual loss and an 
increased risk for further venous thrombotic events. Also, approximately one half of sur-
vivors feel depressed, anxious or experience minor cognitive or language deficits [4, 5]. 
Residual epilepsy has been reported in 10% of the patients. Other thrombotic events such as 
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deep vein thrombosis and pulmonary embolism occur in about 5% of patients and mostly 
within the first year [4, 16]. The risk of VTE is increased in patients with severe thrombo-
philia. Recurrence of CVT is rare (2.8%) and tends to occur within the first year of evolution, 
especially after anticoagulation discontinuation [4, 17]. Severe visual loss due to intracranial 
hypertension is infrequent [5]. It was suggested that LS thrombosis can later induce arteriove-
nous malformations affecting the transverse sinus [1].
The CVT associated with postpartum state has a survival rate of 90% [1, 36]. It is considered 
that the absence of sex-specific risk factors is a strong and independent predictor of poor out-
come in women with CVT [17]. The large majority (88%) of the pregnancies ends in normal 
births, the remaining being prematurely terminated by voluntary or spontaneous abortion; 
nevertheless, the rate of spontaneous abortion was found to be higher in CVT female patients 
[5]. In neonates, the functional outcome is usually normal if asphyxia is not associated [1].
It has been estimated that recanalization of the thrombosed cerebral vein and sinus occurs in 
40–90% of CVT patients, mostly within the first 4 months, being limited thereafter [4, 5, 9]. The 
deep venous system and the cavernous sinus have a higher rate of recanalization; the lowest 
rates were observed in LS thrombosis. Recanalization of the occluded sinus is not related to 
outcome after CVT [5, 9, 14].
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